Sanofi ADR
I · Análisis con IA
En breve
Sanofi researches, manufactures, and markets a broad portfolio of medicines and vaccines, including pediatric vaccines (polio, pertussis, hepatitis), immunology treatments, rare disease therapies, and cancer drugs [Company Overview]. The company operates through partnerships with biotech firms to develop next-generation therapies using AI, protein degradation, and genome editing technologies [Company Overview].
Sanofi is a major French pharmaceutical company with $104,3 billion market cap that develops and sells vaccines, immunology treatments, rare disease therapies, and oncology drugs [Yahoo Finance]. Recent positive phase 2 trial results for efdoralprin alfa in a rare lung disease and AI investments in Alzheimer's research show R&D momentum, though the stock dropped 9% over the past month [Yahoo Finance]. The company is financially healthy with $10,1 billion in free cash flow and a 5,55% dividend yield [Yahoo Finance].
Sanofi is financially healthy with strong cash generation and manageable debt levels [Yahoo Finance].
Puntuación Sentinellis
7,4/10
Preocupaciones moderadas
Capitalización bursátil
$104,3B
Ingresos (12 meses)
EUR 46,7B
Explicaciones
Cómo leemos estas cifras
Guías en lenguaje sencillo · sin cuenta
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LeerPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LeerAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LeerII · Noticias recientes
Qué movió el precio
5 noticias · ordenadas por relevancia
- Macro2026-05-18
Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols
Yahoo Finance
- Macro2026-05-18
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
Yahoo Finance
- Macro2026-05-18
A Look At Sanofi (ENXTPA:SAN) Valuation After Recent Share Price Weakness
Simply Wall St
- Macro2026-05-18
Sanofi Deepens AI And Alzheimer’s Research While Shares Trade Below Targets
Simply Wall St
- Macro2026-05-19
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Yahoo Finance
Premium · gratis con cualquier cuenta
The stock dropped 9% over the past month and has struggled over the past year, signaling investor concern about near-term performance despite longer-term gains [Simply Wall St]
Riesgos
5
Oportunidades
6
Señales de alerta
2
Dirección
10
12 hallazgos más en el informe completo — gratis con cualquier cuenta.
Desbloquea el análisis completo de Sanofi ADR
Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.
- 5 riesgos, 6 oportunidades y 2 señales de alerta — cada uno con su fuente
- Más de 100 métricas financieras con gráficos y comparativas
- Resúmenes completos de noticias con enlaces a las fuentes
- Equipo directivo y remuneración
III · Empresas similares
También te puede interesar
Mismo sector · Salud — o salud financiera comparable
¿La añades a tu lista?